Constellation Pharmaceuticals Inc.
Funding rounds
7 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2019 | $65 M | No. 7 | $50 to $250 million | equity | SEC | |
| Mar 2018 | $99 M | No. 6 | $50 to $250 million | equity | SEC | |
| Sep 2016 | $24 M | No. 5 | $10 to $50 million | equity | SEC | |
| Dec 2015 | $56 M | No. 4 | $50 to $250 million | equity | SEC | |
| Aug 2014 | $5 M | No. 3 | $2 to $10 million | equity | SEC | |
| May 2011 | $15 M | No. 2 | $10 to $50 million | equity, options | SEC | |
| May 2010 | $22 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Constellation Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2019).
SEC Form D · Oct 2019
The industry group it chose in its notices: Biotechnology.
SEC Form D · Oct 2019
That is all the official record says: Constellation Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: the address on record now leads to another company's site.
Investors#
33 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Alexandria Venture Investments, LLC | Venture capital | not stated | not stated | Held Series B, D, E, E-1 and F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Casdin Capital, LLC | Fund or asset manager | not stated | not stated | Held Series E, E-1 and F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Casdin Partners GP, LLC | Fund or asset manager | not stated | not stated | Held Series E, E-1 and F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Casdin Partners Master Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series E, E-1 and F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Casdin Venture Opportunities Fund GP, LLC | Venture capital | not stated | not stated | Held Series E, E-1 and F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Casdin Venture Opportunities Fund, L.P. | Venture capital | not stated | not stated | Held Series E, E-1 and F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Column Group GP, LP | Fund or asset manager | not stated | not stated | Held Series A, B, D, E, E-1 and F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Column Group L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, D, E, E-1 and F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Cormorant Asset Management, LP | Fund or asset manager | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Cormorant Global Healthcare Master Fund, LP | Fund or asset manager | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Cormorant Private Healthcare Fund I, LP | Fund or asset manager | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Deerfield Management Company, L.P. | Fund or asset manager | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Deerfield Mgmt L.P. | Fund or asset manager | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Deerfield Special Situations Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| GSK PLC | Fund or asset manager | not stated | not stated | Held Series B, D, E, E-1 and F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| LG Management, LLC | Fund or asset manager | not stated | not stated | Held Series E, E-1 and F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Mountain Berg Ltd | Company | not stated | not stated | Held Series E, E-1 and F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| OrbiMed Capital GP VI LLC | Fund or asset manager | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| OrbiMed Global Healthcare GP LLC | Other | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Ponoi Capital II, LP | Fund or asset manager | not stated | not stated | Held Series A, B, D, E, E-1 and F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Ponoi Capital, LP | Fund or asset manager | not stated | not stated | Held Series A, B, D, E, E-1 and F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Ponoi II Management, LLC | Fund or asset manager | not stated | not stated | Held Series A, B, D, E, E-1 and F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Ponoi Management, LLC | Fund or asset manager | not stated | not stated | Held Series A, B, D, E, E-1 and F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Precision Onco Ltd | Company | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Regents Of The University Of California | Fund or asset manager | not stated | not stated | Held Series E, E-1 and F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Spur Capital Partners LLC | Fund or asset manager | not stated | not stated | Held Series E, E-1 and F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Spur Ventures II, LP | Venture capital | not stated | not stated | Held Series E, E-1 and F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Third Rock Ventures GP, L.P. | Venture capital | not stated | not stated | Held Series A, B, D, E, E-1 and F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Third Rock Ventures LP | Venture capital | not stated | not stated | Held Series A, B, D, E, E-1 and F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Topspin Biotech Fund II, L.P. | Fund or asset manager | not stated | not stated | Held Series E, E-1 and F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Topspin Fund L.P. | Fund or asset manager | not stated | not stated | Held Series E, E-1 and F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| TRV GP, LLC | Other | not stated | not stated | Held Series A, B, D, E, E-1 and F preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 30 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Adrian G. Senderowicz | Executive officer | Oct 2019 |
| Emma E. Reeve | Executive officer | Oct 2019 |
| Jigar Raythatha | Executive officer | Oct 2019 |
| Karen G. Valentine | Executive officer | Oct 2019 |
| Patrick G. Trojer | Executive officer | Oct 2019 |
| James E. Audia | Executive officer | Sep 2016 |
| Mark A. Goldsmith | Executive officer | Sep 2016 |
| Matthias E. Jaffe | Executive officer | Sep 2016 |
| Michael R. Cooper | Executive officer | Sep 2016 |
| Keith Dionne | Executive officer | Dec 2015 |
| Garen E. Bohlin | Executive officer | Jun 2011 |
| Edward E. Harlow, Jr. | Executive officer | Jun 2010 |
| Kerry K. Reinertsen | Executive officer | Jun 2010 |
| Anthony Evnin | Director | Oct 2019 |
| Elizabeth G. Trehu | Director | Oct 2019 |
| James E. Audia | Director | Oct 2019 |
| Jigar Raythatha | Director | Oct 2019 |
| Mark A. Goldsmith | Director | Oct 2019 |
| Robert A. Tepper | Director | Oct 2019 |
| Scott G. Braunstein | Director | Oct 2019 |
| Steven G. Hoerter | Director | Oct 2019 |
| Peter Svennilson | Director | Apr 2018 |
| Anthony A. Evnin | Director | Sep 2016 |
| Peter A. Svennilson | Director | Sep 2016 |
| Tom A. Maniatis | Director | Sep 2016 |
| David A. Goeddel | Director | Dec 2015 |
| Keith Dionne | Director | Dec 2015 |
| Steven A. Paul | Director | Aug 2014 |
| David Goeddel | Director | Jun 2011 |
| Mark A. Levin | Director | Jun 2011 |
| Robert E. Tepper | Director | Jun 2011 |
| Steven E. Paul | Director | Jun 2011 |
| Robert K. Tepper | Director | Jun 2010 |
About
Company in Cambridge, United States.